Showing results (491-500 of 630) with videos related to
Sort By:
Pageof 63
Dermatology and Therapy|June 26, 2025
Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic DermatitisJonathan I Silverberg, Melinda Gooderham, Andreas Wollenberg, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|November 15, 2025
Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 yearsChristopher G Bunick, Alan D Irvine, Jonathan I Silverberg, et al.The British Journal of Dermatology|December 4, 2023
Burden of atopic dermatitis in paediatric patients: an international cross-sectional studyStephan Weidinger, Eric L Simpson, Jonathan I Silverberg, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|April 28, 2026
Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 yearsMelinda J Gooderham, Jonathan I Silverberg, Marjolein De Bruin-Weller, et al.Journal of Drugs in Dermatology : JDD|January 6, 2026
Racial and Ethnic Disparities in Access to Advanced Therapies for Atopic Dermatitis in the United StatesKatrina Abuabara, Christopher G Bunick, Lara Wine Lee, et al.The Journal of Dermatological Treatment|March 12, 2026
Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitisJonathan I Silverberg, Thomas Bieber, Kilian Eyerich, et al.Journal of the American Academy of Dermatology|March 6, 2020
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOSJonathan I Silverberg, Gil Yosipovitch, Eric L Simpson, et al.The Journal of Pediatrics|May 1, 2022
The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-sectional StudySebastien Barbarot, Jonathan I Silverberg, Abhijit Gadkari, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|August 1, 2023
Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trialEmma Guttman-Yassky, Jonathan I Silverberg, Diamant Thaçi, et al.Journal of Drugs in Dermatology : JDD|June 4, 2025
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Robert Bissonnette, et al.Pageof 63